Sphingosine kinase type 1 inhibitors

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9388121
SERIAL NO

13649221

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Provided are novel compositions and analogs which are useful in a number of applications, indications and diseases, as well as for monitoring pharmakinetics and patient management. These compounds and analogs are applicable to treating tumors of the central nervous system, e.g., glioblastoma (GBM).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
VIRGINIA COMMONWEALTH UNIVERSITY800 EAST LEIGH STREET SUITE 3000 RICHMOND VA 23298
ENZO THERAPEUTICS INC10 EXECUTIVE BLVD FARMINGDALE NY 11735

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Adams, Jeffrey Kroll Fort Washington, US 15 125
Spiegel, Sarah Richmond, US 19 120
Zipkin, Robert Elliot Wynnewood, US 15 103

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 12, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 12, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00